



## **Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update**

**NEW YORK (November 15, 2021)** - Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), today announces financial results for the third quarter ended September 30, 2021 and provides a corporate update.

"The third quarter was transformative for Indaptus as we successfully closed the merger with Decoy Biosystems, Inc. ("Decoy") and completed a \$30 million private placement to support our exciting new clinical programs," said Jeffrey Meckler, Chief Executive Officer of Indaptus. "We are executing to our strategy of advancing Decoy20 as a potential new treatment modality for a variety of cancer indications with unmet medical need. Our goal to enter the clinic with Decoy20 in 2022 remains on track, however, we now plan to file the IND next year as we are in the process of recruiting a Chief Medical Officer to lead our clinical trials. We believe we have a unique opportunity to shape the course of cancer treatment by activating both the innate and adaptive immune systems with our therapeutics and look forward to making our vision a reality."

### **Recent Corporate Highlights**

#### **Received Notice of Allowance for Strategic Patent in Virology**

In September, Indaptus announced that the United States Patent and Trademark Office issued a notice of allowance for claims related to the Company's platform technology in the field of virology. The patent, titled, "Methods of Treatment of Infections Using Bacteria," (Application No.16/584,644) provides broad protection for the application of the Company's platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.

#### **Closed Merger with Decoy Biosystems and Completed \$30 Million Private Placement**

In August, Indaptus closed its previously announced merger with Decoy and the completion of a \$30 million private placement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company's therapeutic focus.

#### **Financial Highlights for Third Quarter Ended September 30, 2021**

Research and development expenses, for the three-month period ended September 30, 2021, were approximately \$0.7 million, a decrease of approximately \$0.7 million, or approximately 48%, compared with approximately \$1.4 million in the three-month period ended September 30, 2020. Research and development expenses for the nine-month period ended September 30, 2021, were approximately \$1.6 million, a decrease of approximately \$0.7 million, or approximately 31%, compared with approximately \$2.3 million in the nine-month period ended September 30, 2020. The decrease for the three and nine-month periods was primarily due to the manufacturing and characterization of Decoy20 during the three and nine months ended September 30, 2020.

General and administrative expenses for the three-month period ended September 30, 2021, were approximately \$2.7 million, an increase of approximately \$2.5 million, or approximately 1,260%, compared with approximately \$0.2 million in the three-month period ended September 30, 2020. General and administrative expenses for the nine-month period ended September 30, 2021, amounted to approximately \$2.9 million, an increase of approximately \$2.4 million, or approximately 456%, compared to approximately \$0.5 million for the nine-month period ended September 30, 2020. The increase for the three and nine-month periods was primarily related to the payroll and related expenses, stock-based compensation expense for stock options issued in August 2021 and professional fees associated with being a public company following the merger.

Loss per share for the three-month period ended September 30, 2021, was approximately \$0.81 compared with approximately \$0.79 for the three-month period ended September 30, 2020. Loss per share for the nine-month period ended September 30, 2021, was approximately \$1.67 compared with approximately \$1.45 for the nine-month period ended September 30, 2020.

As of September 30, 2021, the Company had cash and cash equivalents of approximately \$41.9 million. As of December 31, 2020, the Company had cash and cash equivalents of approximately \$1.6 million.

Net cash used in operating activities was approximately \$7.8 million for the nine-month period ended September 30, 2021, compared with net cash used in operating activities of approximately \$2.4 million for the nine-month period ended September 30, 2020. This increase resulted primarily from an increase in general and administrative expenses and effects of the merger and changes in operating assets and liabilities.

Net cash provided by financing activities for the nine-month period ended September 30, 2021, was approximately \$48.0 million, which was provided by the proceeds from the Company's private placement offering in August 2021 that resulted in net proceeds of approximately \$27.3 million, net proceeds from the merger in the amount of approximately \$15.7 million and the sale of additional Simple Agreements for Future Equity (SAFEs) in the amount of approximately \$5.0 million. Net cash provided by financing activities for the nine-month period ended September 30, 2020, was approximately \$1.2 million, which was provided by the sale of SAFEs.

## **About Indaptus Therapeutics**

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company's approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus' patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy in preclinical models. Tumor eradication by Indaptus technology has demonstrated activation of both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a tumor antigen in pre-clinical models. Indaptus has carried out successful GMP manufacturing of its lead clinical oncology candidate, Decoy20, and is currently completing other IND enabling studies.

## **Forward-Looking Statements**

This press release contains forward-looking statements with the meaning of the Private Securities Litigation Reform Act. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies, plans and prospects. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: Indaptus' plans to develop and potentially commercialize its technology, the timing and cost of Indaptus' planned investigational new drug application and any clinical trials, the completion and receiving favorable results in any clinical trials, Indaptus' ability to obtain and maintain regulatory approval of any product candidate, Indaptus' ability to protect and maintain its intellectual property and licensing arrangements, Indaptus' ability to develop, manufacture and commercialize its product candidates, the risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation, and Indaptus' estimates regarding future revenue, expenses capital requirements and the need for additional financing following the merger. These risks, as well as other risks are discussed in the proxy statement/prospectus that was included in the registration statement on Form S-4 filed with the SEC in connection with the merger. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

### **Investor Contact:**

Will O'Connor  
Stern IR  
+1 212-362-1200  
will@sternir.com

INDAPTUS THERAPEUTICS, INC.

**Unaudited Condensed Consolidated Balance Sheets**

	September 30, 2021	December 31, 2020
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 41,857,222	\$ 1,637,499
Assets held for sale	600,000	-
Prepaid expenses and other current assets	1,397,669	94,500
	<hr/>	<hr/>
Total current assets	43,854,891	1,731,999
	<hr/>	<hr/>
Non-current assets		
Property and equipment, net	4,335	1,349
Other assets	-	44,445
	<hr/>	<hr/>
Total non-current assets	4,335	45,794
	<hr/>	<hr/>
Total assets	\$ 43,859,226	\$ 1,777,793
	<hr/> <hr/>	<hr/> <hr/>
<b>Liabilities and stockholders' equity</b>		
Current liabilities		
Accounts payable and other current liabilities	\$ 5,780,184	\$ 598,365
SAFE agreements	-	1,417,129
	<hr/>	<hr/>
Total current liabilities	5,780,184	2,015,494
	<hr/>	<hr/>

## Commitments and contingent liabilities

### Stockholders' equity (deficit)

Preferred stock; Series Seed; \$0.01 par value; 5,000,000 and 972,335 shares authorized as of September 30, 2021 and December 31, 2020, respectively, 0 and 835,928 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	-	8,359
Common stock; \$0.01 par value, 200,000,000 and 3,185,224 shares authorized as of September 30, 2021 and December 31, 2020, respectively; 8,133,243 and 1,944,672 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	81,332	19,447
Additional paid in capital	50,452,275	7,693,994
Accumulated deficit	(12,454,565)	(7,959,501)
	<hr/>	<hr/>
Total stockholders' equity (deficit)	38,079,042	(237,701)
	<hr/>	<hr/>
Total liabilities and stockholders' equity (deficit)	\$ 43,859,226	\$ 1,777,793
	<hr/> <hr/>	<hr/> <hr/>

### Unaudited Condensed Consolidated Statements of Operations

	Three months ended		Nine months ended	
	September 30,		September 30,	
	2021	2020	2021	2020
Operating expenses				
Research and development	\$ 697,674	\$ 1,349,835	\$ 1,578,512	\$ 2,302,883
General and administrative	2,670,317	196,578	2,932,100	527,830
Total operating expenses	3,367,991	1,546,413	4,510,612	2,830,713
Loss from operations	(3,367,991)	(1,546,413)	(4,510,612)	(2,830,713)
Other income, net	827	3,680	15,548	16,781
Net loss	\$ (3,367,164)	\$ (1,542,733)	\$ (4,495,064)	\$ (2,813,932)
Net loss available to common stockholders per share of common stock, basic and diluted	\$ (0.81)	\$ (0.79)	\$ (1.67)	\$ (1.45)
Weighted average number of shares used in calculating net loss per share, basic and diluted	4,180,744	1,944,672	2,692,770	1,944,672

## Unaudited Condensed Consolidated Statements of Cash Flows

Nine months ended

September

	2021	2020
<b>Cash flows from operating activities:</b>		
Net loss	\$ (4,495,064)	\$ (2,813,932)
<b>Adjustments to reconcile net loss to net cash used in operating activities:</b>		
Depreciation	868	639
Stock-based compensation	836,456	116,872
<b>Changes in operating assets and liabilities:</b>		
Prepaid expenses and other current assets	(1,128,933)	(19,418)
Accounts payable and other current liabilities	(2,964,147)	348,241
	(7,750,820)	(2,367,598)
<b>Cash flows from investing activities:</b>		
Purchases of property and equipment	(3,854)	-
	(3,854)	-
<b>Cash flows from financing activities:</b>		
Proceeds from merger	16,346,622	-
Decoy's transaction costs	(665,627)	-
Issuance of pre-funded warrants and warrants	29,972,727	-
Issuance costs of Private Placement	(2,706,598)	-
Exercise of pre-funded warrants	27,273	-

Proceeds from SAFEs	5,000,000	1,167,129
Net cash provided by financing activities	47,974,397	1,167,129
Net increase (decrease) in cash and cash equivalents	40,219,723	(1,200,469)
Cash and cash equivalents at beginning of period	1,637,499	3,798,955
Cash and cash equivalents at end of period	\$ 41,857,222	\$ 2,598,486

#### Noncash investing and financing activities

Conversion of preferred stock	\$ 8,359	-
Conversion of SAFEs	\$ 6,417,129	-
Liabilities assumed, net of non-cash assets received in reverse merger	\$ 7,616,175	-
Release of deposit upon closing of Merger	\$ 200,000	-

#### Supplemental cash flow disclosures

Cash paid for income taxes	\$ 800	\$ 800
Cash received for interest earned on deposits	\$ 2,362	\$ 12,365